| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/IMT.15.10 |
| P698 | PubMed publication ID | 25917629 |
| P50 | author | Stanley C Jordan | Q96350303 |
| P2093 | author name string | Ashley Vo | |
| Jua Choi | |||
| P2860 | cites work | Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. | Q55034268 |
| Eculizumab and Splenectomy as Salvage Therapy for Severe Antibody-Mediated Rejection After HLA–Incompatible Kidney Transplantation | Q58048136 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma | Q24633761 | ||
| CD20 deficiency in humans results in impaired T cell-independent antibody responses | Q24653638 | ||
| Regulatory B cells: an exciting target for future therapeutics in transplantation | Q27015093 | ||
| Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection | Q28294329 | ||
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 | ||
| IdeS: a bacterial proteolytic enzyme with therapeutic potential | Q33321259 | ||
| Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 | ||
| Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders | Q33385389 | ||
| Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects | Q33388543 | ||
| U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. | Q33403209 | ||
| Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial | Q33412064 | ||
| U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia | Q33415277 | ||
| NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. | Q51676450 | ||
| Blockade of IL-6-signaling inhibits the pathogenesis of CD4+ T cell-mediated lethal graft-versus-host reaction against minor histocompatibility antigen. | Q53273278 | ||
| Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. | Q53551590 | ||
| Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance. | Q53897541 | ||
| Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. | Q54478992 | ||
| Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study | Q33527462 | ||
| Use of bortezomib as anti-humoral therapy in kidney transplantation | Q33627580 | ||
| Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 | ||
| Bortezomib in multiple myeloma: systematic review and clinical considerations | Q33982728 | ||
| Anti-CD30 antibody-based therapy | Q34086171 | ||
| Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation | Q34124202 | ||
| Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. | Q34156748 | ||
| Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study | Q34240404 | ||
| Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation | Q34361643 | ||
| Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial | Q34373536 | ||
| Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials | Q34405616 | ||
| Multifunctional CD40L: pro- and anti-neoplastic activity | Q34422566 | ||
| Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial | Q34429882 | ||
| IL-6 promotes cardiac graft rejection mediated by CD4+ cells | Q35566506 | ||
| Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells | Q35613184 | ||
| Grand challenges in B cell biology | Q35928361 | ||
| B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells | Q35946128 | ||
| Antibody-mediated renal allograft rejection: diagnosis and pathogenesis | Q36759900 | ||
| Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma | Q36822162 | ||
| Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase | Q36852554 | ||
| A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody | Q36887068 | ||
| Chronic alloantibody mediated rejection | Q37058050 | ||
| Cryptic B cell response to renal transplantation | Q37150424 | ||
| The spectrum of antibody-mediated renal allograft injury: implications for treatment | Q37176570 | ||
| Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia | Q37257024 | ||
| Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). | Q37487919 | ||
| B-cell-directed therapies for autoimmune disease | Q37542901 | ||
| Intravenous immunoglobulin a natural regulator of immunity and inflammation | Q37544139 | ||
| Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program | Q37548545 | ||
| Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. | Q37595993 | ||
| The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. | Q37644840 | ||
| Advances in diagnosing and managing antibody-mediated rejection | Q37676032 | ||
| Therapeutic antibodies for autoimmunity and inflammation | Q37736260 | ||
| B-cell targeted therapies in human autoimmune diseases: an updated perspective | Q37781401 | ||
| Desensitization: achieving immune detente | Q37820683 | ||
| Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients | Q37827197 | ||
| Desensitization protocols and their outcome | Q37858260 | ||
| Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation | Q37877263 | ||
| B-cell immunotherapeutics: emerging roles in solid organ transplantation | Q37888431 | ||
| Monitoring and managing graft health in the kidney transplant recipient | Q37898354 | ||
| Bruton tyrosine kinase (BTK) and its role in B-cell malignancy | Q37997075 | ||
| The impact of donor-specific anti-HLA antibodies on late kidney allograft failure | Q38003049 | ||
| Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases | Q38058508 | ||
| Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity | Q38071110 | ||
| B-cell regulation and its application to transplantation | Q38126085 | ||
| The emerging role of TH17 cells in organ transplantation. | Q38161321 | ||
| Future agents and treatment directions in multiple myeloma | Q38172300 | ||
| The biology and medical implications of interleukin-6. | Q38207010 | ||
| Update on the use of biologics in lupus. | Q38236793 | ||
| Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype | Q39180411 | ||
| An Integrated View of Molecular Changes, Histopathology and Outcomes in Kidney Transplants | Q39829568 | ||
| Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study | Q39883589 | ||
| Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study | Q42268606 | ||
| Reduced T-dependent humoral immunity in CD20-deficient mice | Q42275151 | ||
| Antibodies to watch in 2014. | Q42461882 | ||
| Summary of FDA antibody-mediated rejection workshop | Q42598786 | ||
| Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation | Q43181339 | ||
| Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells | Q43487327 | ||
| Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients | Q43829155 | ||
| Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab | Q43873334 | ||
| Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA. | Q44470243 | ||
| Quantifying the risk of incompatible kidney transplantation: a multicenter study. | Q44753304 | ||
| Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions | Q45342440 | ||
| Identifying specific causes of kidney allograft loss. | Q45810388 | ||
| Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy. | Q46095776 | ||
| Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy | Q46350406 | ||
| Rituximab and intravenous immune globulin for desensitization during renal transplantation | Q46477840 | ||
| Cancer's true breakthroughs | Q46703935 | ||
| Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database | Q46767796 | ||
| Blocking of experimental arthritis by cleavage of IgG antibodies in vivo | Q46973412 | ||
| Desensitization offers hope to highly HLA-sensitized patients for a longer life expectancy after incompatible kidney transplant | Q47569936 | ||
| Humoral Antibodies in Renal Allotransplantation in Man | Q47784760 | ||
| Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study | Q47862153 | ||
| Epratuzumab for systemic lupus erythematosus | Q48078160 | ||
| Secukinumab in plaque psoriasis--results of two phase 3 trials | Q49167189 | ||
| Anti-B cell therapy with rituximab as induction therapy in renal transplantation. | Q50627295 | ||
| B-cell receptor signaling in chronic lymphocytic leukemia. | Q50674847 | ||
| Desensitization in HLA-incompatible kidney recipients and survival. | Q51018759 | ||
| P433 | issue | 4 | |
| P921 | main subject | desensitization | Q2700499 |
| P304 | page(s) | 377-398 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Immunotherapy | Q18713038 |
| P1476 | title | Achieving incompatible transplantation through desensitization: current perspectives and future directions | |
| P478 | volume | 7 |
| Q30397952 | Desensitization: Overcoming the Immunologic Barriers to Transplantation |
| Q37099107 | Immune Tolerance for Autoimmune Disease and Cell Transplantation |
| Q26766471 | Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation |
| Q33842250 | Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study |
| Q89621291 | Phenotypic and Transcriptomic Lymphocytes Changes in Allograft Recipients After Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients |
| Q39730031 | Progress in Desensitization of the Highly HLA Sensitized Patient |
| Q38726037 | The Incremental Cost of Incompatible Living Donor Kidney Transplantation: A National Cohort Analysis |
Search more.